Sugi Predict

Sugi Predict / Compounds / SCHEMBL532613

SCHEMBL532613

SCHEMBL532613

Clc1ccc(Br)c(CBr)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS3 P29474 1/20 0.42
▸ NOS1 P29475 1/20 0.42
▸ NOS2 P35228 1/20 0.42
▸ IDO1 P14902 4/20 0.41
▸ CYP3A4 P08684 4/20 0.41
▸ HIF1A Q16665 3/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ HPGD P15428 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ ALOX15 P16050 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ HTT P42858 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ SLC22A1 O15245 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ HSP90AA1 P07900 1/20 0.41
▸ HSPD1 P10809 1/20 0.41
▸ HSPA5 P11021 1/20 0.41
▸ ALOX12 P18054 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5293792 1.00 NOS3 (0.42) NOS3NOS1NOS2IDO1CYP3A4
SCHEMBL30819621 1.00 NOS3 (0.42) NOS3NOS1NOS2IDO1CYP3A4
SCHEMBL2560634 0.83 NOS3 (0.44) NOS3NOS1NOS2IDO1CYP3A4
SCHEMBL7024324 0.83 HIF1A (0.54) NOS3NOS1NOS2IDO1CYP3A4
SCHEMBL12713145 0.82 NOS3 (0.41) NOS3NOS1NOS2IDO1CYP3A4
SCHEMBL17332138 0.81 NOS3 (0.42) NOS3NOS1NOS2IDO1CYP3A4
SCHEMBL979069 0.81 PYCR1 (0.47) IDO1CYP3A4HIF1AMEN1HPGD
SCHEMBL29485890 0.81 PYCR1 (0.47) IDO1CYP3A4HIF1AMEN1HPGD
SCHEMBL30089455 0.80 IDO1 (0.44) IDO1CYP3A4HIF1AMEN1HPGD
SCHEMBL384040 0.80 IDO1 (0.44) IDO1CYP3A4HIF1AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747251-A1 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-27 — — EP disclosed
EP-4712969-A1 CYCLIN INHIBITORS Circle Pharma, Inc. (US) 2026-03-25 — — EP disclosed
WO-2025226862-A1 CYCLIN INHIBITORS CIRCLE PHARMA, INC. (US) 2025-10-30 — — WO disclosed
WO-2025226861-A1 CYCLIN INHIBITORS CIRCLE PHARMA, INC. (US) 2025-10-30 — — WO disclosed
EP-4605409-A2 CYCLIN INHIBITORS Circle Pharma, Inc. (US) 2025-08-27 — — EP disclosed
WO-2025125695-A2 CHEMICAL COMPOUNDSID50000167790940 P. DOC 2025-05-07 FILING NO.:19 MEDCHEMICA CONSULTANCY LTD (GB) 2025-06-19 — — WO disclosed
CN-119954853-A Heterocyclic compound and application thereof 北京云基科技股份有限公司 2025-05-09 — — CN disclosed
WO-2025019479-A1 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2025-01-23 — — WO disclosed
US-20240408169-A1 CYCLIN INHIBITORS CIRCLE PHARMA, INC. 2024-12-12 — — US disclosed
US-20240218021-A1 CYCLIN INHIBITORS CIRCLE PHARMA, INC. 2024-07-04 — — US disclosed
WO-2005013892-A9 HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE ANACOR PHARMACEUTICALS INC (US) 2005-04-14 — — WO disclosed
US-20050054644-A1 Hydrolytically-resistant boron-containing therapeutics and methods of use ANACOR PHARMACEUTICALS, LLC 2005-03-10 — — US disclosed
WO-2005013892-A2 HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE ANACOR PHARMACEUTICALS, INC. (US) 2005-02-17 — — WO disclosed
US-6770666-B2 A THERAPEUTIC AGENT FOR TREATING HEPATITIS C, BASED ON POLYMERASE INHIBITORY ACTIVITY JAPAN TOBACCO INC. (JP) 2004-08-03 — — US disclosed
US-20040097438-A1 Fused-ring compounds and use thereof as drugs JAPAN TOBACCO INC. (JP) 2004-05-20 — — US disclosed
WO-2004037796-A2 1-(4-BENZYL-PIPERAZIN-1-YL)-3-PHENYL-PROPENONE DERIVATIVES NOVARTIS AG (CH) 2004-05-06 — — WO disclosed
US-20040082635-A1 Viricide against hepatitis virus; polymerase inhibitor JAPAN TOBACCO INC. (JP) 2004-04-29 — — US disclosed
EP-1400241-A1 FUSED CYCLIC COMPOUNDS AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2004-03-24 — — EP disclosed
US-20030050320-A1 Fused-ring compounds and use thereof as drugs JAPAN TOBACCO INC. (JP) 2003-03-13 — — US disclosed
EP-1162196-A1 FUSED-RING COMPOUNDS AND USE THEREOF AS DRUGS JAPAN TOBACCO INC. (JP) 2001-12-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082635-A1 Viricide against hepatitis virus; polymerase inhibitor HAVCR2, ZC3HAV1, POLR1C NOS3 2759/4885NOS1 2002/4885NOS2 2771/4885
US-20030050320-A1 Fused-ring compounds and use thereof as drugs HAVCR2, ZC3HAV1, HLA-C NOS3 1232/4885NOS1 1466/4885NOS2 1632/4885
US-20240218021-A1 CYCLIN INHIBITORS CCNI, CCNC, CDK2 NOS3 4298/4885NOS1 3979/4885NOS2 4155/4885
US-20040097438-A1 Fused-ring compounds and use thereof as drugs HAVCR2, ZC3HAV1, SLC10A1 NOS3 701/4885NOS1 858/4885NOS2 1033/4885
US-20240408169-A1 CYCLIN INHIBITORS CCNI, CDK2, CDK1 NOS3 4058/4885NOS1 3813/4885NOS2 3907/4885
US-20050054644-A1 Hydrolytically-resistant boron-containing therapeutics and methods of use BTD, GAA, GBA3 NOS3 3558/4885NOS1 3945/4885NOS2 3823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.